Therapy in Amyotrophic Lateral Sclerosis (TAME)

Summary

The purpose of this study is to determine if memantine at up to 20 mg twice a day when used in conjunction with riluzole, can slow down the disease progression of patients with ALS including potentially improving their neuropsychiatric changes, as well as determine if serum biomarkers can be used both as a diagnostic and a prognostic marker in patients with ALS. Funding Source: FDA - Orphan Products Development (OPD)

Timeline

Start

2018-11-07

Primary completion

2021-07-22

Completion

2021-07-22

Drugs

Indications